

## Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

## EQA round: AP1/22 - Antithrombotic Agents

Deadline: 01.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set 1</b>														
<b>(108) Apixaban</b>					33							33	33	100%
Samples and groups		[µg/L]												
<b>Sample A1</b>		216	14	6,6	33	CVP	216	6,1	25%	162	270	33	33	100%
(38) IL		224	8,6	3,8	10	0						10		
(63) Sysmex		214	17	7,8	13	0						13		
(94) Stago		212	15	7,0	8	0						8		
Other					2	0						2		
							1x 162, 1x 179							
<b>Sample B1</b>		417	24	5,8	33	CVP	417	10	25%	312	522	33	33	100%
(38) IL		434	14	3,2	10	0						10		
(63) Sysmex		411	33	8,0	13	0						13		
(94) Stago		412	16	4,0	8	0						8		
Other					2	0						2		
							1x 162, 1x 179							
<b>Set 2</b>														
<b>(109) Dabigatran</b>					34							34	31	91%
Samples and groups		[µg/L]												
<b>Sample A2</b>		283	45	16	34	CVP	283	19	34%	186	380	34	31	91%
(38) IL		287	47	16	10	0						10		
(63) Sysmex		277	37	13	15	1						15		
(94) Stago		304	50	16	6	0						6		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
<b>Sample B2</b>		98,1	17	18	34	CVP	98,1	7,2	34%	64,7	132	34	33	97%
(38) IL		100	12	12	10	0						10		
(63) Sysmex		92,6	16	17	15	0						15		
(94) Stago		115	12	10	6	0						6		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
<b>Set 3</b>														
<b>(110) Rivaroxaban</b>					40							40	40	100%
Samples and groups		[µg/L]												
<b>Sample A3</b>		305	26	8,5	40	CVP	305	10	25%	228	382	40	40	100%
(38) IL		285	7,4	2,6	12	0						12		
(63) Sysmex		318	27	8,3	17	0						17		
(94) Stago		304	12	3,9	8	0						8		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							
<b>Sample B3</b>		92,8	7,3	7,9	40	CVP	92,8	2,8	25%	69,6	116	40	40	100%
(38) IL		93,4	5,8	6,2	12	0						12		
(63) Sysmex		94,2	7,9	8,3	17	0						17		
(94) Stago		88,5	8,2	9,2	8	0						8		
Other					3	0						3		
							1x 149, 1x 162, 1x 179							

st\_kn\_p

End of report

Printed: 06.04.2022